Abstract
Introduction
Guidelines advocate the use of spirometry to assess pulmonary function in asthmatic patients. Commonly used measures include forced expiratory volume in 1 s (FEV1), forced expiratory ratio (FEV1/FVC), and forced mid-expiratory flow between 25 and 75 % of forced vital capacity (FEF25–75). Impulse oscillometry (IOS) is an effort-independent test performed during tidal breathing. IOS may be used to assess the total and central airway resistance at 5 Hz (R5) and 20 Hz (R20), respectively, and hence derive the peripheral airway resistance from the difference (R5–R20). We compared spirometry and IOS as tests of global airway function (i.e., FEV1, FEV1/FVC, R5) and putative measures of small airways function (i.e., FEF25–75, R5–R20) and their relationship to oral steroid and short-acting beta-agonist (SABA) use as surrogates for long-term asthma control.
Methods
Spirometry and IOS measurements from physician-diagnosed asthmatics were linked to a health informatics database for oral steroid and SABA use 1 year prior to the index measurements.
Results
Four hundred forty-two patients had both spirometry and IOS, mean FEV1 = 86 % predicted, 94 % on ICS, median dose 800 µg/day. IOS and spirometry measures were equally predictive of impaired asthma control for both oral steroid and SABA use. For oral steroid use, the adjusted odds ratio, OR (95 % CI) is as follows: FEV1 < 80 %: 1.56(0.99–2.47), p = 0.056; FEV1/FVC < 0.70: 1.67(1.03–2.69), p = 0.037; FEF25–75 < 60 %: 1.84(1.18–2.86), p = 0.007; R5 > 150 %: 1.91(1.25–2.95), p = 0.003; and R5–R20 > 0.1 kPa L−1 s 1.73(1.12–2.66), p = 0.013. For SABA use, the adjusted OR (95 % CI) is as follows: FEV1 < 80 %: 2.22(1.43–3.44), p < 0.001; FEV1/FVC < 0.70: 2.26(1.44–3.57), p < 0.001; FEF25–75 < 60 %: 2.51(1.65–3.82), p < 0.001; R5 > 150 %: 1.76(1.18–2.63), p = 0.006; and R5–R20 > 0.1 kPa L−1 s: 2.94(1.94–4.46), p < 0.001.
Conclusion
Spirometry or IOS measurements were equally useful as potential markers of asthma control in persistent asthmatic patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bateman ED, Hurd SS, Barnes PJ et al (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31:143–178
Lipworth B (2013) Targeting the small airways asthma phenotype: if we can reach it, should we treat it? Ann Allergy Asthma Immunol 110:233–239
Miller MR, Hankinson J, Brusasco V et al (2005) Standardisation of spirometry. Eur Respir J 26:319–338
(2008) British guideline on the management of asthma. Thorax 63 Suppl 4: iv1–121
Shi Y, Aledia AS, Galant SP et al (2013) Peripheral airway impairment measured by oscillometry predicts loss of asthma control in children. J Allergy Clin Immunol 131:718–723
Rao DR, Gaffin JM, Baxi SN et al (2012) The utility of forced expiratory flow between 25% and 75 % of vital capacity in predicting childhood asthma morbidity and severity. J Asthma 49:586–592
Lipworth B, Manoharan A, Anderson W (2014) Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med 2:497–506
Gonem S, Natarajan S, Desai D et al (2014) Clinical significance of small airway obstruction markers in patients with asthma. Clin Exp Allergy 44:499–507
Juniper EF, Price DB, Stampone PA et al (2002) Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 121:1824–1832
Price D, Martin RJ, Barnes N et al (2010) Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 126(511–8):e1–e10
Barnes N, Price D, Colice G et al (2011) Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 41:1521–1532
Conflict of interest
AM has received support from Teva to attend the 2013 European Respiratory Society Congress and Chiesi to attend the 2014 meeting. WJA has received support from Chiesi to attend the 2013 European Respiratory Society Congress. BJL is on the Speaker Bureau for Teva and Advisory Board for Chiesi and Teva. JL has no competing interests to declare. The Scottish Centre for Respiratory Research has received unrestricted educational grants from Chiesi and Teva and participated in a multicentre study sponsored by Teva.
Ethical standards
This manuscript complies with the current laws of the United Kingdom
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manoharan, A., Anderson, W.J., Lipworth, J. et al. Assessment of Spirometry and Impulse Oscillometry in Relation to Asthma Control. Lung 193, 47–51 (2015). https://doi.org/10.1007/s00408-014-9674-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-014-9674-6